Second edition — Nov 8–10, 2027 — Baltimore, MD Abstract submission — Oct 12, 2026 Registration — Nov 01, 2026
ACRT 2027 / Talks

Talks

Leaders in cancer biology, immunology, and translational oncology delivering the plenary program at ACRT 2027.

§01
Confirmed
Khalid Shah, MS, PhD
Confirmed

Khalid Shah, MS, PhD

Brigham and Women's Hospital · Harvard Medical School

Director, Center for Stem Cell and Translational Immunotherapy; engineers gene-edited cell therapies for brain tumors.

Douglas Green, PhD
Confirmed

Douglas Green, PhD

St. Jude Children's Research Hospital

Peter C. Doherty Chair of Immunology; a leading authority on apoptosis and cell death in cancer.

Ellen Puré, PhD
Confirmed

Ellen Puré, PhD

The Wistar Institute

Studies the tumor stroma and FAP; pioneered stromal-targeted CAR T approaches for solid tumors.

§02
Invited — not yet confirmed

The organizing committee is in discussion with the following speakers. Names will move to "Confirmed" as invitations are accepted.

Ellen Puré, PhD
Invited

Bert Vogelstein, MD

Clayton Professor of Oncology, Co-Director, Ludwig Center — Johns Hopkins Kimmel Cancer Center

A pioneer of cancer genetics, Dr. Vogelstein proposed the model of cancer as the sequential accumulation of mutations in oncogenes and tumor suppressor genes, and co-discovered key genes including APC and mutant p53 in colorectal cancer.

Ellen Puré, PhD
Invited

Michael Pishvaian, MD, PhD

Johns Hopkins Kimmel Cancer Center

A gastrointestinal oncologist focused on pancreatic and refractory colorectal cancers, Dr. Pishvaian is known for advancing precision-medicine and molecular-profiling approaches that match patients to targeted therapies.

Ellen Puré, PhD
Invited

Elizabeth Jaffee, MD

Deputy Director, Sidney Kimmel Comprehensive Cancer Center — Johns Hopkins

An international leader in cancer immunotherapy, Dr. Jaffee co-developed a pancreatic cancer vaccine and is a past president of the American Association for Cancer Research (2018–2019).